Home › Funds › Venrock Adviser, LLC › CGEM
Venrock Adviser, LLC position in CGEM
CULLINAN THERAPEUTICS INC · Health Care
Venrock Adviser, LLC reported holding 1,379,965 shares of CGEM (CULLINAN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$25.1M, representing 0.76% of its reported portfolio and ranking #22 among its reported holdings. Venrock Adviser, LLC has disclosed CGEM holdings in 9 of the last 9 reported quarters, going back to Q2 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Venrock Adviser, LLC's CGEM position evolved
Venrock Adviser, LLC first disclosed a stake in CGEM in Q2 2024 at 1,379,965 shares (US$24.1M). The position peaked in Q2 2026 at 1,379,965 shares, worth US$25.1M. Across 9 filings, Venrock Adviser, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 1,379,965 shares valued at US$25.1M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 1.38M | $24.07M | New |
| Q3 2024 | 1.38M | $23.10M | Hold |
| Q4 2024 | 1.38M | $16.81M | Hold |
| Q1 2025 | 1.38M | $10.45M | Hold |
| Q2 2025 | 1.38M | $10.39M | Hold |
| Q3 2025 | 1.38M | $8.18M | Hold |
| Q4 2025 | 1.38M | $14.28M | Hold |
| Q1 2026 | 1.38M | $19.61M | Hold |
| Q2 2026 | 1.38M | $25.13M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CGEM and 13F data
CGEM (CULLINAN THERAPEUTICS INC) is a Health Care company. 37 other funds we track also report a position in CGEM — the largest reported positions include MPM BioImpact LLC (US$177.2M), Lynx1 Capital Management LP (US$163.2M), BVF INC/IL (US$104.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CGEM
- MPM BioImpact LLC 9.73M sh · $177.21M · Q2 2026
- Lynx1 Capital Management LP 8.96M sh · $163.23M · Q2 2026
- BVF INC/IL 5.75M sh · $104.72M · Q2 2026
- Kynam Capital Management, LP 3.11M sh · $56.71M · Q2 2026
- RTW INVESTMENTS, LP 2.36M sh · $43.05M · Q2 2026
- Siren, L.L.C. 1.89M sh · $34.48M · Q2 2026
- Blue Owl Capital Holdings LP 1.54M sh · $28.04M · Q2 2026
- BOOTHBAY FUND MANAGEMENT, LLC 1.08M sh · $19.71M · Q2 2026
- Affinity Asset Advisors, LLC 875.76K sh · $15.95M · Q2 2026
- BOONE CAPITAL MANAGEMENT LLC 704.44K sh · $12.83M · Q2 2026
- Elmind Capital, LP 690.00K sh · $12.56M · Q2 2026
- TWIN FOCUS CAPITAL PARTNERS, LLC 595.49K sh · $10.84M · Q2 2026
More on Venrock Adviser, LLC
FAQ
How long has Venrock Adviser, LLC held CGEM?
Venrock Adviser, LLC has disclosed CGEM holdings in 9 of the last 9 reported quarters, going back to Q2 2024.
What is Venrock Adviser, LLC's current position in CGEM?
As of Q2 2026, Venrock Adviser, LLC holds 1.38M shares of CGEM (CULLINAN THERAPEUTICS INC), valued at $25.13M, representing 0.76% of its reported portfolio and ranking #22.
Has Venrock Adviser, LLC been buying or selling CGEM?
In the latest 13F filing (Q2 2026), Venrock Adviser, LLC held unchanged its position in CGEM. The position peaked in Q2 2026 at 1.38M shares.
Which other funds hold CGEM?
Other major institutional holders of CGEM include MPM BioImpact LLC, Lynx1 Capital Management LP, BVF INC/IL, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.